Laboratory Co. of America Holdings (NYSE:LH) EVP Der Vaart Sandra D. Van Sells 1,000 Shares

Laboratory Co. of America Holdings (NYSE:LH) EVP Der Vaart Sandra D. Van sold 1,000 shares of Laboratory Co. of America stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $239.42, for a total value of $239,420.00. Following the completion of the transaction, the executive vice president now directly owns 2,670 shares of the company’s stock, valued at $639,251.40. This represents a 27.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Laboratory Co. of America Trading Up 0.7 %

Shares of NYSE LH opened at $241.24 on Tuesday. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $247.99. The stock has a market cap of $20.18 billion, a price-to-earnings ratio of 46.66, a P/E/G ratio of 1.97 and a beta of 1.05. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.66. The company’s fifty day moving average is $226.43 and its 200-day moving average is $217.39.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.02. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The company had revenue of $3.28 billion during the quarter, compared to the consensus estimate of $3.26 billion. During the same quarter in the prior year, the firm earned $3.38 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. Equities research analysts predict that Laboratory Co. of America Holdings will post 14.53 EPS for the current year.

Laboratory Co. of America Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Tuesday, November 26th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 annualized dividend and a yield of 1.19%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 55.71%.

Hedge Funds Weigh In On Laboratory Co. of America

Large investors have recently modified their holdings of the business. CreativeOne Wealth LLC acquired a new stake in shares of Laboratory Co. of America in the 1st quarter valued at approximately $282,000. EP Wealth Advisors LLC bought a new position in shares of Laboratory Co. of America in the 1st quarter valued at about $211,000. Advisors Asset Management Inc. increased its stake in shares of Laboratory Co. of America by 99.3% during the 1st quarter. Advisors Asset Management Inc. now owns 2,178 shares of the medical research company’s stock worth $476,000 after purchasing an additional 1,085 shares during the last quarter. 1832 Asset Management L.P. raised its holdings in shares of Laboratory Co. of America by 2.6% in the 1st quarter. 1832 Asset Management L.P. now owns 9,657 shares of the medical research company’s stock valued at $2,110,000 after purchasing an additional 244 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in Laboratory Co. of America by 2.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 114,488 shares of the medical research company’s stock valued at $25,012,000 after purchasing an additional 2,934 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on LH. Barclays boosted their target price on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Friday, October 25th. Jefferies Financial Group boosted their price objective on shares of Laboratory Co. of America from $245.00 to $265.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Truist Financial increased their price objective on Laboratory Co. of America from $255.00 to $275.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Evercore ISI dropped their target price on Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating for the company in a research report on Tuesday, September 24th. Finally, Robert W. Baird raised their price target on Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $255.92.

Laboratory Co. of America Company Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.